Showing 291-300 of 2500 results for "".
- Pilot Study: ESWT Improves Wound Healing Before Surgeryhttps://practicaldermatology.com/news/pilot-study-eswt-improves-wound-healing-before-surgery/2460032/Extracorporeal shockwaves (ESWT) initiated within the operation field prior to surgery may improve wound healing and minimize scar formation, according to a pilot study in Lasers in Surgery and Medicine (LSM). The
- Sunscreen Chemicals Found in the Bloodstream: Experts React to the New Findingshttps://practicaldermatology.com/news/sunscreen-chemicals-found-in-bloodstream-experts-react-to-the-new-findings/2460023/Several active ingredients found in different sunscreens enter the bloodstream at levels that far exceed the FDA's recommended threshold without a government safety inspection, a new study in Journal of the American M
- Cutera Hosts Beauty Talk with Sadick and Sadickhttps://practicaldermatology.com/news/cuter-hosts-beauty-talk-with-sadick-and-sadick/2459960/Dermatologist Neil Sadick, MD and his daughter Sydney Sadick, an in-the-know fashion journalist, talked about everything from state-of-the-art skin brightening treatments to the newest injectables and how to get svelte without sweating or surgery at
- More Positive Results Seen with Endo's Injectable Cellulite Treatmenthttps://practicaldermatology.com/news/more-positive-results-for-endos-injectable-cellulite-treatment/2459965/Endo International plc’s injectable cellulite treatment collagenase clostridium histolyticum ("CCH") showed a clinically meaningful and statistically significant improvement compared to placebo for all primary and secondary endpoints in a Phase 2
- LEO Pharma Focuses on Translational Medicine, Appoints Dr. Adam B. Raff as Director & Medical Advisorhttps://practicaldermatology.com/news/leo-pharma-strengthens-focus-on-translational-medicine-with-appointment-of-dr-adam-b-raff-as-director-medical-advisor/2459942/LEO Pharma has appointed Adam B. Raff, MD, PhD as Director and Medical Advisor in Translational Medicine, effective January 28. Dr. Raff’s primary objective will be to support LEO Pharma’s ambitions to advance science within dermatology through translational medicine, the company says
- Dermatology Hall of Fame to Recognize Industry Pioneershttps://practicaldermatology.com/news/dermatology-hall-of-fame-to-recognize-industry-pioneers/2459941/The Dermatology Hall of Fame will honor its first inductees February 28, 2019, in Washington, DC. The organization, founded in 2018, was established to recognize and honor past and present luminaries within all areas of dermatology. “The field of dermatology has been furthered by tr
- AD, Suicidal Thoughts and Attempts Linkedhttps://practicaldermatology.com/news/ad-suicidal-thoughts-and-attempts-linked/2457543/Patients with eczema may be more likely to have suicidal thoughts and attempts compared to their counterparts without eczema, according to a new study in JAMA Dermatology. Res
- Psoriasis Plus Hypertension Equals Greater Need for Heart Surgeryhttps://practicaldermatology.com/news/psoriasis-plus-hypertension-equals-greater-need-for-cardiovascular-interventions/2457559/Patients with psoriasis and hypertension need more cardiovascular procedures and surgeries than hypertensive patients without psoriasis, a new study in the Journal of Dermatology suggests. In 5.62 year
- Castle Creek Pharmaceuticals Gets FDA Fast Track Designation for Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-gets-fda-fast-track-designation-for-diacerein-1-ointment-for-ebs/2457655/The U.S. Food & Drug Administration (FDA) granted fast track status to Castle Creek Pharmaceuticals, LLC’s diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS). "Fast Track designation is an
- Almirall: Phase 3 Studies of KX2-391 for AK Meet Primary Endpointshttps://practicaldermatology.com/news/almirall-phase-3-studies-of-kx2-391-for-ak-meet-primary-endpoints/2457676/Both Phase 3 studies of KX2-391met the primary endpoint of complete clearance of actinic keratosis (AK) lesions at day 57 within the face or scalp treatment areas, Almirall, SA reports. Each study achieved statistical significance on this endpoint. The double-blind, randomized, vehi